|Northwest Biotherapeutics, Inc.|
4800 Montgomery Lane
United States - Map
Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
|Ms. Linda F. Powers J.D.,
Chairperson, Chief Exec. Officer, Pres, Chief Financial Officer and Principal Accounting Officer
|Dr. Alton L. Boynton Ph.D.,
Founder, Chief Scientific Officer, Sec. and Director
|Dr. Marnix L. Bosch Ph.D., MBA,
Chief Technical Officer
|Mr. Leslie J. Goldman ,
Sr. VP of Bus. Devel.
|Dr. Anthony E. Maida III, MA, MBA, Ph.D.,
Sr. VP of Clinical Research
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|